Is CKD Screening for All Over 35 Cost Effective?
Screening all adults in the United States for CKD starting at age 35 could be cost effective for the quality of life-years gained.
Screening all adults in the United States for CKD starting at age 35 could be cost effective for the quality of life-years gained.
Millions of COVID patients may have undiagnosed acute kidney injury, a condition where the kidneys fail to filter waste from the blood.
The National Kidney Foundation and the American Society of Nephrology have outlined a new race-free approach to diagnosing kidney disease.
The guidance outlines scientific evidence and information on national and international standards, test methods, and specifications for fluid-resistant and impermeable gowns and coveralls used in healthcare.
Read MoreFujirebio’s latest offering is a third-generation assay that accurately measures biologically active parathyroid hormone levels resulting from disorders of calcium metabolism.
Read MoreThe National Kidney Foundation, the American Society for Clinical Pathology, and the nation’s leading laboratories and clinical laboratory associations have announced a collaboration to remove barriers to testing for chronic kidney disease.
Read MoreThe point-of-care test for the detection of infection in patients on peritoneal dialysis enables warning of infection within 10 minutes.
Read MoreThe noninvasive urine-based test for kidney rejection diagnosis utilizes metabolic biomarker networks.
Read MoreThe NGAL protein has been designed to provide a high level of purity that minimizes the risk of interferences due to contaminants.
Read MoreImmunoassay developers are staying current with new releases year round.
Read MoreWorkshop attendees can expect to understand improvements in CKD diagnostic testing, and to examine other opportunities for analytical improvement focusing on the measurement of bone markers, parathyroid hormone, and vitamin D compounds.
Read MoreTo determine how recommendations for chronic kidney disease testing in laboratory and point-of-care environments are shifting, CLP spoke to Robert H. Christenson, PhD, professor of pathology and medical and research technology at the University of Maryland School of Medicine and past president of the American Association for Clinical Chemistry.
Read MoreOrtho-Clinical Diagnostics has announced the availability of the NephroCheck test system, the first such test designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury within 12 hours of assessment.
Read MoreWith the prevalence of diabetes continuing on an upward trajectory both in the United States and overseas, healthcare professionals are continuing to search for more effective methods of preventing, detecting, and treating the disease.
Read MoreFDA has granted market clearance for the first test that can help determine whether membranous glomerulonephritis is due to the body’s rejection of its own kidney tissue (autoimmune) or to another cause, such as infection.
Read MoreThe company produces comprehensive third-party designer drug quality controls for use with any methodology, on any testing platform.
Read MoreExamining 12 major types of cancer, scientists at Washington University School of Medicine in St Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body.
Read MoreResearchers at Moffitt Cancer Center, Tampa, Fla, and colleagues at the University of South Florida have discovered a mechanism that explains how some cancer cells hijack a biological process to potentially activate cell growth and the survival of cancer gene expression.
Read More